Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates
GILD Stock Soars on HIV Drug Data: Gilead’s shares gained after the company announced upbeat results from an interim analysis of a second late-stage study evaluating the use of the company’s ...
The Pharma Letter2d
Upstream Bio goes public amid spate of IPOs
Upstream Bio has filed for an IPO on Nasdaq under the symbol "UPB," following recent biotech listings. The company focuses on ...
pharmaphorum2d
Respiratory biotech Upstream joins Nasdaq IPO surge
The Waltham, Massachusetts-based company has advanced its TSLP inhibitor verekitug into a pair of phase 2 trials in severe ...
Yahoo Finance3d
REGN Nov 2024 1035.000 call
Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNP Current treatment options leave many patients with uncontrolled disease and ...
Regeneron, SNY Win FDA Approval for a Broader Dupixent Label
REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.
Pharmaceutical Technology5d
FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze delivery tech
Roche has secured approval from the US Food and Drug Administration for Ocrevus Zunovo with Halozyme's Enhanze drug delivery ...
Pharmaceutical Technology5d
Regeneron’s Dupixent approved as first adolescent CRSwNP treatment
The FDA has expanded the approval of Dupixent to include adolescents aged 12 to 17 years with inadequately controlled CRSwNP.
PipelineReview.com6d
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Following Priority Review, Dupixent is now available to patients as young as 12 yearswith inadequately controlled CRSwNP ...